The study about anti-depression mechanism of dopamine partial agonist

The study about anti-depression mechanism of dopamine partial agonist - The study about anti-depression mechanism of dopamine partial agonist

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044939

Enrollment

Registered

2021-10-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

Single dose of aripiprazole 3mg Single dose of same amount of placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with major depressive disorder 2. Age between 20 and 60 years at the time of consent 3. Treated with escitalopram or sertraline and with any residual symptoms 4. Has give his/her written consent by his/her free will with sufficient explanation and understanding for participation in this study

Exclusion criteria

Exclusion criteria: 1. history of serious physical disease or head injury 2. history of neuropsychiatric disease other than major depressive disorder 3. history of manic or hypomanic episodes. 4. history of treatment with aripiprazole within 6 months. 5. being treated with antipsychotic drugs, dopamine agonist drugs, or brexpiprazole. 6. any other person deemed inappropriate by the physician.

Design outcomes

Primary

Measure	Time frame
Neural response of ventral striatum during moneta ry incentive delay task measured by functional MRI	—

Countries

Japan

Contacts

Public ContactNaoki Hashimoto

Hokkaido University Department of Psychiatry, Graduate School of Medicine

hashinao@med.hokudai.ac.jp0117065160

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026